GRUENDELPARTNER advises WMS on investment in ROTOP

Wachstumsfonds Mittelstand Sachsen (WMS) is investing in ROTOP together with healthcare specialists GENUI and SHS Capital.

ROTOP Pharmaka GmbH, founded in 2000 and based in Dresden-Rossendorf, is a leading supplier of radiopharmaceutical products. Radioactive pharmaceuticals are being used more and more frequently, both for diagnostic applications and for therapeutic purposes; in nuclear medicine, for example, for imaging or for targeted therapy in the treatment of certain types of cancer. The use of radiopharmaceutical products offers the advantage of highly targeted efficacy and largely avoids damage to healthy tissue.

GRUENDELPARTNER advised WMS on the legal aspects of this financing round.

GRUENDELPARTNER's M&A, Venture Capital, Private Equity practice group is one of the most experienced and strongly staffed advisory units in Central Germany and supports investors and entrepreneurs in all phases of development, in particular in company formation, company development, company financing and all exit processes.